H. Mahumutha*, Nilsha Anil, R. Ramprasad, J. Amutha Iswaraya Devi, N. Venkateshan
Department of Pharmacy, Arulmigu Kalasalingam College of Pharmacy, Krishnankoil-626126
A B S T R A C T
To focus on NAFLD about its prevalence and it’s treatment NAFL Dreferred to as nonalcoholic fatty liver disease (NAFlD)or nonalcoholic steato hepatitis (NASH) with or without fibrosis to hepato cellular carcinoma. Accumulation of excess fat deposit over the liver. This fat deposit is also seen among alcoholics. Alcoholics fatty liver disease is seen in patients who drink or no alcohol. NAFlD is termed as fatty liver and cirrhosis occur when the liver sustains substantial damage liver cells are replaced by scar tissue which result in the inability of the liver to work properlyliver enzyme such as gama- glutamyl transferase(GGT), AlT ( alanine amino transferase)and aspartate amino transferase (AST) have recently been suggested as risk factors for cardio vascular disease, impact on myocardial infarction (or) ischemic stroke .serologic methods or liver biopsy to evaluate the severity of NAFLD.fatty liver is a very common disorder up to 20%of adults and approximately 8% of children are affected.non alcoholic steato hepatitis the more severe form of fatty liver is seen in around 20% of the obese individuals NAFLD is associated with various metabolic risk factors such as , obesity and diabetes and NAFLD is the one of the most common chronic liver disease and Diabetes MEDICINES reduce liver fat in nonalcoholic fatty liver disease. it has found that Empagliflozin a newer treatment for type 2 diabetes reduces liver fat with NAFLD and diabetes NASH may progress cirrhosis of the liver and liver Cancer no approved medication treating NASH (or) NAFLD agent like metformin, pioglitazone and vit E limited success in reducing liver fat our results suggest that Empagliflozin may help in treat NAFLD.